So why can't they get the damn qiagen.com website to work properly?
I mean at every year end
Same procedure as every year at Q. LAY OFFS ???
AND NEW SHARES FOR P.S. and R.S. ONLY ???
DJ DGAP-CMS: QIAGEN N.V.: Release of a capital market information
Dow Jones Newswires
QIAGEN N.V. / Share buy-back
Dissemination of a Post-admission Duties announcement, transmitted by
DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure according to Art. 4 Para. 2 of the Regulation (EC) No. 2273/2003
The share repurchase program, announced by QIAGEN N.V. in an ad hoc
announcement dated July 30, 2013, will continue on December 18, 2013.
In the time period until March 14, 2014, a third tranche of common shares
of the Company having a total purchase price of up to the EUR equivalent
amount of USD 45 million (without ancillary purchasing costs) shall be
repurchased on the electronic trading platform of the Frankfurt Stock
Exchange (XETRA ) exclusively. The tranche is limited by the repurchase of
a total number of max. 2,500,000 shares. The maximum purchase price per
share (excluding ancillary purchase costs) will not exceed by more than 10%
the average closing price for the last five trading days prior to the day
of purchase on the Frankfurt Stock Exchange.
The purpose of the share repurchase is to hold the shares in treasury in
order to satisfy obligations from exchangeable debt instruments and/or
employee share-based remuneration plans. The Managing Board of QIAGEN N.V.,
upon authorization of the Supervisory Board, is thus exercising the
authorization by the Annual General Meeting on June 26, 2013 to acquire own
shares. The repurchase of additional tranches will be decided separately
and details will be announced separately.
The repurchase program will be carried out on behalf and account of QIAGEN
N.V. through a financial institution commissioned by the Company. The
financial institution will decide on the timing of the share purchase
independently, without being influenced by the Company.
This tranche of the share repurchase program will be implemented in
accordance with the trading terms of Art. 5 of the Regulation No. 2273/2003
of the Commission of December 22, 2003 (EC Regulation). In accordance with
the EC Regulation, no purchase price may be paid that exceeds the price of
the last independent trade or the highest current independent bid on the
Frankfurt Stock Exchange. The higher of both values is decisive. In
accordance with the EC Regulation, no more than 25% of the average daily
volume of shares on the Frankfurt Stock Exchange may be acquired. The
average volume of shares is based on the average daily volume traded in the
twenty stock exchange trading days preceding the date of the purchase.
The share repurchase program may be suspended and resumed at any time, in
line with applicable statutory regulations.
The transactions will be announced in a manner compliant with the
requirements of Art. 4, Para. 4 of the EC Regulation no later than on the
seventh trading day following their conclusion.
As previously communicated, QIAGEN N.V. has in previous tranches of the
share repurchase program between September 10 and October 11, and November
27 and December 13, 2013 already repurchased 919,321 shares for the EUR
equivalent amount of USD 20 million.
In addition, QIAGEN N.V. will provide regular updates on the progress of
the share repurchase program at www.qiagen.com.
Venlo, December 17, 2013
The Managing Board
QIAGEN has quite a few arrogant pricks that they are still entitled to their overcharged customer base. Funny, had some kool-aid drinking kid tell one of my colleagues that we had better not mess with their bigger accounts. Truth is, all of their accounts are in my crosshairs, and I will be reaping the just rewards sooner than later.
R&D are controlled by number cruncher and bean counters like most R&D Departments this time
Because the damn website was redone by outside contractors in India and it certainly seems like no one inside tested it before they launched it.
And parts of R&D are actually developing products that are growing. HPV was one fucker of a drain on R&D resources for quite some time. Ducks are in a much better row now.
It is sad to hear that Q is only possible to grow through acquisition, not through their own R&D.
looks like the core extraction kits will soon be distributed by VWR, means another round of QIAGEN layoffs. VWR was dumped by Illumina and needs another sucker to maintain a minimum of presence.
More information about formatting options